Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model
20/5 13:52
(RTTNews) - Pasithea Therapeutics Corp. (KTTA) announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory mil...